据新华社旧金山电，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标 志着脑机接口技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化， 截至1月5日上午收盘，该板块指数大涨12.56%至6245.59点，超十只概念股收获"20CM"涨停。 据Neuralink官网及马斯克公开发言内容，截至2025年9月份，该公司已完成12例脑机接口设备人体植入 手术，临床试验参与者累计使用设备时长超1.5万小时，患者可通过意念实现光标操控、文字输入甚至 机械臂辅助进食等操作，设备实际运行稳定性达标率超98%。同时，第二代手术机器人实现技术升级， 将单根电极植入时间从17秒压缩至1.5秒，整体手术时长从6小时缩短至20分钟内；成本端也实现大幅下 降，单台设备植入成本从早期百万美元级降至10万美元以内，全自动化手术落地后有望进一步下探至5 万美元区间。 《证券日报》记者注意到，A股相关上市公司早已在脑机接口赛道展开布局，从设备研发到临床应用多 维度切入，试图抢占行业发展先机 ...

Market Overview - The A-share market saw a strong opening on January 5, with the Shanghai Composite Index returning to 4000 points, closing at 4011.45, up 1.07% [1] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [1] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [3] Stock Performance - A total of 4064 stocks rose, with 99 stocks hitting the daily limit, while 1236 stocks declined [3] - The sectors that performed well included insurance, medical devices, semiconductors, and gaming, with brain-computer interface concept stocks experiencing significant gains [3] Sector Highlights Brain-Computer Interface - Brain-computer interface stocks surged, with several companies hitting the daily limit [6] - Notable performers included Xiangyu Medical, Guanhao Biological, Meihua Medical, Aipeng Medical, and Lepu Medical, all recording a 20% increase [6][7] - Elon Musk's Neuralink announced plans for large-scale production of brain-computer interface devices by December 31, 2026, which is expected to revolutionize the field by reducing invasiveness [9] Semiconductor Sector - The semiconductor sector also showed strength, with multiple stocks reaching their daily limit [10] - Key performers included Dongwei Semiconductor and *ST Tianlong, both achieving a 20% increase [11] - TSMC announced it received U.S. government approval to import chip manufacturing equipment to its Nanjing facility in 2026, which is a positive development for the sector [12] Insurance Sector - The insurance sector experienced a rally, with significant gains from major companies [13] - Xinhua Insurance rose by 7.53%, China Pacific Insurance by 6.16%, and China Life Insurance by over 5% [13][14] - The insurance industry reported a total premium income of 57.629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [14]

Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].

政策端也持续加码支持。国家药监局近期在北京召开脑机接口医疗器械工作推进会，明确表示将加快相 关产品的审评审批流程，推动创新器械更快上市应用。 国金证券指出，在医疗器械创新政策密集落地 背景下，脑机接口作为前沿交叉领域，正迎来从科研验证向临床及消费场景拓展的关键窗口期。 （文章来源：每日经济新闻） 医疗器械ETF（562600）大涨4.36%。截止2025年12月30日，医疗器械ETF脑机接口含量达20.91%。 消息面上，行业迎来多重催化。特斯拉CEO埃隆·马斯克近日在社交媒体透露，其旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备的"大规模生产"。这一表态被市场视为该技术迈向商业化的重 要信号。 与此同时，由OpenAI首席执行官Sam Altman联合创立的脑机接口初创公司Merge Labs宣布将分拆为独 立实体，专注于开发基于超声波的非侵入式脑信号读取技术。该方案无需植入电极，即可实现对大脑活 动的大范围、高精度解读，有望大幅降低技术门槛与临床风险。 早盘脑机接口概念小幅高开，随后震荡上行，截止10点57分，乐普医疗、美好医疗、翔宇医疗、伟思医 疗、迈普医学封板涨停。 ...

1月5日， 脑机接口板块持续大涨，截至发稿，板块指数涨幅已超11%。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 编辑丨瑜见 倍益康30%涨停，美好医疗、三博脑科、熵基科技、翔宇医疗、诚益通等10股20%涨停，创新医疗、荣 泰健康、南京熊猫、三七互娱等涨停。 | 代码 | 名称 | 式唱 | 息金额 | 息而值 | 现价 | | --- | --- | --- | --- | --- | --- | | 920199 | 倍益康 | +29.98% | 1.96 Z | 30.62 G | 44.96 | | 688767 | 博拓生物 | +20.01% | 6.27 Z | 67.71 Z | 45.34 | | 301293 | 三博脑科 | +20.01% | 7.04Z | 1 45.8亿 | 70.78 | | 301363 | 美好医疗 | +20.00% | 1.98 Z | 164.2 乙 | 28.86 | | 301330 | শ্ব # 技 | +20.00% | 7.25 Z | 93.34 Z | 39.66 | | 300887 | 谱尼测试 | + ...

1月5日， 脑机接口板块持续大涨，截至发稿，板块指数涨幅已超11%。 倍益康30%涨停，美好医疗、三博脑科、熵基科技、翔宇医疗、诚益通等10股20%涨停，创新医疗、 荣泰健康、南京熊猫、三七互娱等涨停。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 编辑丨瑜见 | 代码 | 名称 | 涨幅量 | 息金额 | 息市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 920199 | 倍益康 | +29.98% | 1.96 Z | 30.62 乙 | 44.96 | | 688767 | 博拓生物 | +20.01% | 6.27 Z | 67.71 Z | 45.34 | | 301293 | 三博脑科 | +20.01% | 7.04 Z | 145.8亿 | 70.78 | | 301363 | 美好医疗 | +20.00% | 1.98 乙 | 164.2 乙 | 28.86 | | 301330 | 腐基科技 | +20.00% | 7.25 Z | 93.34 乙 | 39.66 | | 300887 | 谱尼测试 | +20 ...

早盘中，人脑工程板块表现活跃。板块内9只个股涨停。三博脑科、翔宇医疗、美好医疗20CM涨停， 熵基科技涨超19%，爱朋医疗、诚益通、麦澜德涨超17%，博拓生物涨超15%，伟思医疗涨超13%，狄 耐克、乐普医疗涨超11%，塞力医疗、岩山科技、荣泰健康、创新医疗、南京熊猫、盈趣科技涨停。 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 美好医疗 | 28.86 | 4.81 | 20.00% | | 翔宇医疗 | 72.60 | 12.10 | 20.00% | | 爰朋医疗 | 32.61 | 4.86 | 17.51% | | 乐普医疗 | 17.55 | 1.74 | 11.01% | | 创新医疗 | 23.66 | 2.15 | 10.00% | | 三七互娱 | 25.96 | 2.36 | 10.00% | | 赛诺医疗 | 21.05 | 1.81 | 9.41% | | 汉威科技 | 57.55 | 3.95 | 7.37% | | 冠昊生物 | 14.88 | 1.03 | 7.44% | | 北陆药业 | 8.35 | 0.41 | 5. ...

Group 1 - The brain-computer interface (BCI) sector is experiencing a significant surge, with companies like Beikang, Sanbo Brain Science, and Xiangyu Medical reaching their daily price limits, driven by Elon Musk's announcement regarding Neuralink's plans for large-scale production of BCI devices by 2026 [1] - Neuralink's new automated surgical approach, which allows electrode wires to penetrate the dura mater without removal, aims to reduce the invasiveness of traditional devices and optimize efficiency and costs through automation [1] - Merge Labs, co-founded by OpenAI's CEO Sam Altman, is spinning off to focus on a new generation of ultrasound-based BCI technology that can interpret brain signals without the need for implanted electrodes [1] Group 2 - According to Open Source Securities, Neuralink's anticipated large-scale production and automated surgical methods, along with Merge's ultrasound technology, signify a transition from clinical validation to commercial scalability for BCIs, moving them from "medical trial tools" to "widely available products" [2] - The BCI industry is poised for high growth driven by technological breakthroughs, policy support, and synergies with robotics, with the global BCI market projected to reach approximately $12.4 billion by 2034, reflecting a CAGR of 17% from 2025 to 2034 [2] - The recent expectations for Neuralink's mass production and technological advancements are expected to benefit related A-share BCI companies [2]

消息面上，大摩预期，今年中国人形机器人可出货1.4万台，未来数年将逐年翻倍增长，2034年突破百 万台。 另据每经报道，当地时间2025年12月31日，埃隆.马斯克在社交媒体上表示，其脑机接口公司Neuralink 将于2026年开始对脑机接口设备进行"大规模生产"，还将在脑机植入方式上实现创新。 1月5日电，机器人概念反复活跃，倍益康、翔宇医疗、伟思医疗、熵基科技等涨20%，五洲新春走出4 连板，斯菱智驱涨超15%，双双续创历史新高，汉威科技、蓝思科技、雷迪克、博杰股份等冲高。 | 序号 | 代码 | 名称 | 0 | 最新 | 涨幅% J | | --- | --- | --- | --- | --- | --- | | 1 | 920199 | 倍益康 | 事 | 44.96 | 29.98 | | 2 | 688626 | 翔宇医疗 | 1 | 72.60 | 20.00 | | 3 | 688580 | 伟思医疗 | | 58.08 | 20.00 | | 4 | 301330 | 嫡基科技 | 1 | 39.66 | 20.00 | | 5 | 300753 | 爱朋医疗 | 1 | 33.30 ...

1月5日盘中科创板股翔宇医疗涨停，截至09:36，股价报72.60元，成交3.23亿元，换手率2.80%，振幅 4.13%。 科创板个股中，截至发稿上涨的有482只，下跌的有113只，涨幅居前的有翔宇医疗、麦澜德、博拓生物 等，分别上涨20.00%、17.12%、16.44%，跌幅居前的有富吉瑞、铂力特、有研粉材等，分别下跌 10.62%、10.42%、5.66%。 资金面上，翔宇医疗上一交易日主力资金净流入1421.81万元，近5日净流入6316.46万元。 融资融券数据显示，该股最新（12月31日）两融余额为1.95亿元，其中，融资余额为1.94亿元，较上一 个交易日减少17.85万元，降幅为0.09%；融券余额为38.12万元，较上一个交易日增加0.43万元，增幅为 1.15%。近10日两融余额合计增加2339.00万元，增幅为13.66%，其间融资余额增长13.65%，融券余额增 长19.73%。（数据宝） （文章来源：证券时报网） ...